Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI302 in Diabetic Macular Edema
NCT06908876Phase 2Active, not recruiting
- Sponsor
- Innovent Biologics
- Start
- Apr 2025
- Primary completion
- Dec 2026
- Modality
- Bispecific Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of efdamrofusp alfa in diabetic macular edema (DME) (3 arms), sponsored by Innovent Biologics. Primary endpoint: Best Corrected Visual Acuity change from baseline at 16 weeks. Started Apr 2025; status: active, not recruiting.
02
Drugs
efdamrofusp alfa
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT06908876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06908876.